Niagen Bioscience, Inc. NAGE R2K
Healthcare · Biotechnology · United States
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
READ MORE ›$3.86
-64.33% 1Y
Market & Price
Market Cap
$307.43M
Current Price
$3.86
High / Low (52W)
$14.41 / $3.65
Beta
2.17
Valuation
Stock P/E
18.38
Industry PE
23.65
Forward P/E
12.06
PEG Ratio
-
Book Value
$1.03
Price to Book
3.73
P/S
2.36
EV/EBITDA
20.39
Dividend Yield
-
Profitability & Returns
ROCE
16.53%
ROE
27.07%
ROA
7.09%
Profit Margin
14.29%
Op Margin
5.01%
EPS (Latest Qtr)
$0.07
EPS (TTM)
$0.21
Balance Sheet & Liquidity
Debt/Equity
3.13
Quick Ratio
3.48
Current Ratio
4.61
Debt
$2.58M
Total Assets
$106.41M
Current Assets
$96.81M
Working Capital
$76.89M
Ownership
Promoter Holding
29.25%
Chg in Prom Hold
-
FII / Inst Holding
47.22%
Chg in FII Hold
-0.12%
Financial Snapshot
Enterprise Value
$244.25M
Total Revenue (TTM)
$130.42M
EBITDA
$11.98M
Free Cash Flow
$-1.86M
Operating Cash Flow
$4.43M
Shares Outstanding
79.64M
Gross Margin
64.28%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
21.56%
Profit 5Y
68.36%
Revenue (YoY)
3.30%
Earnings (YoY)
16.70%
PROS
- Strong return on equity of 27.1%.
- Compounding revenue at 21.6% over 5 years.
- Profit CAGR of 68.4% over 5 years.
CONS
- Trading 73.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NAGE Niagen Bioscience, Inc. R2K | 3.86 | 18.38 | $307.43M | - | 16.53% | 27.07% | 21.56% | 68.36% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Jan 2015 | Apr 2015 | Jul 2015 | Oct 2015 | Jan 2016 | Apr 2016 | Jul 2016 | Oct 2016 | Dec 2016 | Apr 2017 | Jul 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 0 | 4.22M | 6.08M | - | 6.57M | 7.80M | 8.12M | 10.05M | 11.10M | 12.05M | 14.35M | 15.29M | 14.18M | 14.68M | 17.70M | 17.31M | 17.26M | 16.73M | 17.06M | 22.56M | 20.32M | 19.50M | 22.15M | 22.74M | 25.58M | 30.48M | 31.12M | 33.99M | 33.84M | 31.47M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.15M | 10.89M | 12.06M | 12.13M | 11.50M |
| Gross Profit | 1.52M | 1.42M | 1.93M | 2.47M | 2.48M | 1.60M | 2.84M | 3.67M | 1.86M | 2.01M | 1.62M | 2.11M | 2.92M | 3.83M | 3.14M | 3.85M | 4.36M | 5.30M | 6.25M | 6.75M | 8.31M | 9.09M | 8.45M | 9.23M | 10.81M | 10.58M | 10.53M | 10.04M | 10.21M | 13.52M | 12.36M | 11.97M | 13.46M | 13.69M | 16.24M | 19.33M | 20.23M | 21.93M | 21.70M | 19.98M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.56M | 17.04M | 17.69M | 19.60M | 18.40M |
| Operating Income | -647.43K | -1.10M | -906.08K | -184.06K | 177.13K | -1.24M | 32.07K | 158.81K | -924.16K | -2.17M | -1.77M | -2.65M | -3.18M | -8.78M | -8.40M | -7.94M | -8.60M | -8.37M | -7.18M | -6.89M | -5.89M | -3.69M | -4.20M | -7.36M | -5.55M | -8.84M | -7.73M | -6.39M | -3.06M | -1.97M | -2.32M | -1.15M | -731.00K | -256.00K | 1.60M | 4.77M | 3.19M | 4.24M | 2.10M | 1.58M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.14M | 3.54M | 4.59M | 2.47M | 2.04M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.23M | 3.74M | 4.80M | 4.42M | 6.74M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 168.00K | 128.00K | 222.00K | 292.00K | 417.00K |
| Net Income | -659.65K | -1.23M | -1.03M | -315.19K | -3.72K | -1.43M | 255.62K | -82.67K | -954.39K | -2.15M | -1.93M | -2.76M | 2.14M | -8.82M | -8.44M | -8.05M | -8.61M | -8.34M | -7.75M | -7.20M | -5.90M | -3.71M | -4.21M | -7.38M | -5.57M | -8.86M | -7.74M | -6.40M | -985.00K | -1.90M | -2.19M | -959.00K | -492.00K | -15.00K | 1.88M | 5.06M | 3.61M | 4.58M | 4.13M | 6.32M |
| Diluted EPS | - | - | -0.03 | -0.01 | - | - | 0.01 | 0.00 | -0.03 | -0.06 | -0.05 | -0.07 | 0.04 | -0.17 | - | - | -0.16 | - | - | - | - | -0.06 | -0.07 | -0.12 | -0.08 | -0.13 | -0.11 | -0.09 | -0.01 | -0.03 | -0.03 | -0.01 | -0.01 | 0.00 | 0.02 | 0.06 | 0.04 | 0.05 | 0.05 | 0.07 |
| R&D Expense | - | - | 121.09K | 175.41K | 188.69K | - | 464.07K | 751.73K | 772.80K | - | 664.00K | 850.00K | 1.04M | - | 1.44M | 1.41M | 1.35M | 1.17M | 1.07M | 1.04M | 919.00K | 895.00K | 841.00K | 787.00K | 1.00M | 996.00K | 1.08M | 1.25M | 1.22M | 1.19M | 1.36M | 1.24M | 2.10M | 1.32M | 1.29M | 1.26M | 1.57M | 1.79M | - | 1.48M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 21.20M | 31.56M | 46.29M | 59.26M | - | 72.05M | 83.57M | 99.60M | 129.42M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 29.25M | 32.79M | 38.01M | 46.23M |
| Gross Profit | 2.94M | 2.47M | 2.28M | 3.13M | 5.33M | 7.53M | 10.39M | 10.48M | 16.05M | 25.77M | 35.27M | - | 42.80M | 50.78M | 61.59M | 83.19M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 61.42M | 56.38M | 53.86M | 68.89M |
| Operating Income | -2.02M | -7.86M | -11.64M | -4.39M | -5.23M | -2.07M | -2.91M | -16.38M | -33.17M | -31.30M | -19.85M | - | -18.63M | -5.60M | 7.73M | 14.30M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -16.74M | -3.89M | 9.21M | 15.75M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -16.54M | -4.94M | 8.86M | 18.19M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 305.00K | 810.00K |
| Net Income | -2.05M | -7.89M | -11.66M | -4.42M | -5.39M | -2.77M | -2.93M | -11.38M | -33.32M | -32.15M | -19.93M | - | -16.54M | -4.94M | 8.55M | 17.38M |
| Diluted EPS | -0.04 | -0.12 | - | - | - | - | - | - | - | - | -0.33 | - | -0.24 | -0.07 | 0.11 | 0.20 |
| R&D Expense | - | 96.79K | 142.00K | 134.04K | 513.67K | 891.60K | 2.52M | 4.01M | 5.48M | 4.42M | 3.42M | 3.83M | 4.83M | 4.96M | 6.02M | 6.33M |
Compounded Sales Growth
| 5 Years: | 21.56% |
| 1 Year: | 3.30% |
Compounded Profit Growth
| 5 Years: | 68.36% |
| 1 Year: | 16.70% |
Stock Price Performance
| 1 Year: | -64.33% |
| 6 Months: | -45.17% |
| 3 Months: | -23.56% |
| 1 Month: | -18.91% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2010 | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 6.51M | 6.27M | 9.03M | 8.99M | 11.52M | 18.75M | 19.75M | 62.72M | 42.23M | 40.25M | 38.36M | - | 54.06M | 54.96M | 68.28M | 106.41M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 46.57M | 49.53M | 64.10M | 96.81M |
| Cash & Equivalents | - | - | - | - | - | - | - | - | - | - | 18.81M | 16.70M | - | 20.29M | 27.17M | 44.51M | 64.64M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.68M | 14.53M | 9.19M | 20.42M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.48M | 5.23M | 7.77M | 9.74M |
| Total Liabilities | - | - | - | 5.04M | 3.32M | 7.52M | 13.47M | 9.78M | 8.89M | 15.05M | 19.80M | 21.93M | - | 25.39M | 26.51M | 22.18M | 29.87M |
| Current Liabilities | - | 1.14M | 3.34M | 4.76M | 2.84M | 4.98M | 9.59M | 8.87M | 8.09M | 14.44M | 15.06M | 16.48M | - | 17.87M | 20.62M | 17.95M | 19.92M |
| Long Term Debt | - | - | - | - | - | 1.98M | 3.35M | 0 | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.26M | 3.28M | 2.65M | 2.82M |
| Total Equity | 1.05M | 4.94M | 2.56M | 3.99M | 5.67M | 4.00M | 5.27M | 9.97M | 53.83M | 27.18M | 20.45M | 16.42M | - | 28.67M | 28.46M | 46.09M | 76.53M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.57M | 74.98M | 77.33M | 79.71M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.66M | -4.10M | -10.12M | -3.91M | -2.58M | -2.11M | -2.94M | -9.80M | -20.91M | -20.44M | -10.60M | - | -15.10M | 7.12M | 12.11M | 13.50M |
| Investing Cash Flow | -199.14K | -176.66K | -76.56K | 998.65K | 1.59M | -647.73K | -1.72M | 4.60M | -1.77M | -249.00K | -165.00K | - | -334.00K | -143.00K | -143.00K | -292.00K |
| Financing Cash Flow | 4.62M | 2.47M | 10.30M | 4.65M | 2.69M | 4.34M | 754.27K | 48.95M | -90.00K | 16.88M | 8.65M | - | 7.65M | -90.00K | 5.37M | 6.92M |
| Capital Expenditure | -169.14K | -150.66K | -24.55K | -137.35K | -123.10K | -525.23K | -1.50M | -1.17M | -1.32M | -743.00K | - | - | -334.00K | -148.00K | -163.00K | -292.00K |
| Free Cash Flow | -2.83M | -4.25M | -10.14M | -4.04M | -2.70M | -2.64M | -4.44M | -10.97M | -22.23M | -21.18M | - | - | -15.43M | 6.97M | 11.95M | 13.21M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -7.78M | 6.88M | 17.34M | 20.13M |
| Share Buybacks | - | - | -8.20K | - | - | - | - | 0 | 404.00K | - | - | - | - | - | 0 | 251.00K |
Ratios (Annual)
Figures in %.
| Metric | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | 49.4% | 50.9% | 55.7% | 59.5% | - | 59.4% | 60.8% | 61.8% | 64.3% |
| Operating Margin % | - | - | - | - | - | - | - | -77.2% | -105.1% | -67.6% | -33.5% | - | -25.9% | -6.7% | 7.8% | 11.0% |
| Net Margin % | - | - | - | - | - | - | - | -53.7% | -105.6% | -69.4% | -33.6% | - | -23.0% | -5.9% | 8.6% | 13.4% |
| ROE % | -41.6% | -308.2% | -292.0% | -78.0% | -134.8% | -52.5% | -29.4% | -21.1% | -122.6% | -157.2% | -121.3% | - | -57.7% | -17.4% | 18.5% | 22.7% |
| ROCE % | -37.6% | -268.7% | -272.4% | -71.3% | -80.0% | -22.5% | -26.7% | -30.0% | -119.4% | -124.3% | -90.7% | - | -51.5% | -16.3% | 15.4% | 16.5% |
Shareholding Pattern
Insiders
29.25%
Institutions
47.22%
Public Float
66.75%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 4.86% | 3.87M | $14.94M |
| 2 | SteelPeak Wealth, LLC | 4.24% | 3.37M | $13.02M |
| 3 | Arrowstreet Capital, Limited Partnership | 2.99% | 2.38M | $9.18M |
| 4 | Vanguard Capital Management LLC | 2.70% | 2.15M | $8.30M |
| 5 | Tieton Capital Management, LLC | 2.55% | 2.03M | $7.83M |
| 6 | Qube Research & Technologies Ltd | 2.15% | 1.71M | $6.62M |
| 7 | UBS Group AG | 1.76% | 1.41M | $5.43M |
| 8 | Geode Capital Management, LLC | 1.69% | 1.34M | $5.19M |
| 9 | Renaissance Technologies, LLC | 1.67% | 1.33M | $5.13M |
| 10 | Goldman Sachs Group Inc | 1.57% | 1.25M | $4.83M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NAGE
No recent headlines available.